- Tytuł:
- Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study
- Autorzy:
- Źródło:
- In The Lancet Oncology November 2022 23(11):1430-1440
Czasopismo naukowe